Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function

Elisavet Serti, Xenia Chepa-Lotrea, Yun Ju Kim, Meghan Keane, Nancy Fryzek, T. Jake Liang, Marc Ghany, Barbara Rehermann

Research output: Contribution to journalArticle

Abstract

Background & Aims Chronic hepatitis C virus infection activates an intrahepatic immune response, leading to increased expression of interferon (IFN)-stimulated genes and activation of natural killer (NK) cells - the most prevalent innate immune cell in the liver. We investigated whether the elimination of hepatitis C virus with direct-acting antiviral normalizes expression of IFN-stimulated genes and NK cell function. Methods We used multicolor flow cytometry to analyze NK cells from the liver and blood of 13 HCV-infected patients who did not respond to treatment with pegylated interferon and ribavirin. Samples were collected before and during IFN-free treatment with daclatasvir and asunaprevir and compared with samples from the blood of 13 healthy individuals (controls). Serum levels of chemokine C-X-C motif ligand (CXCL) 10 or CXCL11 were measured by enzyme-linked immunosorbent assay. Results Before treatment, all patients had increased levels of CXCL10 or CXCL11 and a different NK cell phenotype from controls, characterized by increased expression of HLA-DR, NKp46, NKG2A, CD85j, signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). NK cells from patients also had increased degranulation and decreased production of IFNγ and tumor necrosis factor α compared with NK cells from controls. Nine patients had an end-of-treatment response (undetectable virus) and 4 had virologic breakthrough between weeks 4 and 12 of therapy. A rapid decrease in viremia and level of inflammatory cytokines in all patients was associated with decreased activation of intrahepatic and blood NK cells; it was followed by restoration of a normal NK cell phenotype and function by week 8 in patients with undetectable viremia. This normalized NK cell phenotype was maintained until week 24 (end of treatment). Conclusions Direct-acting antiviral-mediated clearance of HCV is associated with loss of intrahepatic immune activation by IFNα, which is indicated by decreased levels of CXCL10 and CXCL11 and normalization of NK cell phenotype and function.

Original languageEnglish (US)
Article number59663
Pages (from-to)190-200
Number of pages11
JournalGastroenterology
Volume149
Issue number1
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Virus Diseases
Natural Killer Cells
Hepacivirus
Interferons
STAT1 Transcription Factor
Phenotype
Therapeutics
Viremia
Antiviral Agents
Tumor Necrosis Factor-alpha
Chemokine CXCL10
Ribavirin
Liver
HLA-DR Antigens
Transcriptional Activation
Interferon-gamma
Blood Cells
Flow Cytometry
Enzyme-Linked Immunosorbent Assay

Keywords

  • Immune Regulation
  • ISG
  • NS3 Inhibitor
  • NS5A Inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Serti, E., Chepa-Lotrea, X., Kim, Y. J., Keane, M., Fryzek, N., Liang, T. J., ... Rehermann, B. (2015). Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology, 149(1), 190-200. [59663]. https://doi.org/10.1053/j.gastro.2015.03.004

Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. / Serti, Elisavet; Chepa-Lotrea, Xenia; Kim, Yun Ju; Keane, Meghan; Fryzek, Nancy; Liang, T. Jake; Ghany, Marc; Rehermann, Barbara.

In: Gastroenterology, Vol. 149, No. 1, 59663, 01.07.2015, p. 190-200.

Research output: Contribution to journalArticle

Serti, E, Chepa-Lotrea, X, Kim, YJ, Keane, M, Fryzek, N, Liang, TJ, Ghany, M & Rehermann, B 2015, 'Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function', Gastroenterology, vol. 149, no. 1, 59663, pp. 190-200. https://doi.org/10.1053/j.gastro.2015.03.004
Serti, Elisavet ; Chepa-Lotrea, Xenia ; Kim, Yun Ju ; Keane, Meghan ; Fryzek, Nancy ; Liang, T. Jake ; Ghany, Marc ; Rehermann, Barbara. / Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. In: Gastroenterology. 2015 ; Vol. 149, No. 1. pp. 190-200.
@article{6e16ec9db1654b57bf2dd97b773f311e,
title = "Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function",
abstract = "Background & Aims Chronic hepatitis C virus infection activates an intrahepatic immune response, leading to increased expression of interferon (IFN)-stimulated genes and activation of natural killer (NK) cells - the most prevalent innate immune cell in the liver. We investigated whether the elimination of hepatitis C virus with direct-acting antiviral normalizes expression of IFN-stimulated genes and NK cell function. Methods We used multicolor flow cytometry to analyze NK cells from the liver and blood of 13 HCV-infected patients who did not respond to treatment with pegylated interferon and ribavirin. Samples were collected before and during IFN-free treatment with daclatasvir and asunaprevir and compared with samples from the blood of 13 healthy individuals (controls). Serum levels of chemokine C-X-C motif ligand (CXCL) 10 or CXCL11 were measured by enzyme-linked immunosorbent assay. Results Before treatment, all patients had increased levels of CXCL10 or CXCL11 and a different NK cell phenotype from controls, characterized by increased expression of HLA-DR, NKp46, NKG2A, CD85j, signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). NK cells from patients also had increased degranulation and decreased production of IFNγ and tumor necrosis factor α compared with NK cells from controls. Nine patients had an end-of-treatment response (undetectable virus) and 4 had virologic breakthrough between weeks 4 and 12 of therapy. A rapid decrease in viremia and level of inflammatory cytokines in all patients was associated with decreased activation of intrahepatic and blood NK cells; it was followed by restoration of a normal NK cell phenotype and function by week 8 in patients with undetectable viremia. This normalized NK cell phenotype was maintained until week 24 (end of treatment). Conclusions Direct-acting antiviral-mediated clearance of HCV is associated with loss of intrahepatic immune activation by IFNα, which is indicated by decreased levels of CXCL10 and CXCL11 and normalization of NK cell phenotype and function.",
keywords = "Immune Regulation, ISG, NS3 Inhibitor, NS5A Inhibitor",
author = "Elisavet Serti and Xenia Chepa-Lotrea and Kim, {Yun Ju} and Meghan Keane and Nancy Fryzek and Liang, {T. Jake} and Marc Ghany and Barbara Rehermann",
year = "2015",
month = "7",
day = "1",
doi = "10.1053/j.gastro.2015.03.004",
language = "English (US)",
volume = "149",
pages = "190--200",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function

AU - Serti, Elisavet

AU - Chepa-Lotrea, Xenia

AU - Kim, Yun Ju

AU - Keane, Meghan

AU - Fryzek, Nancy

AU - Liang, T. Jake

AU - Ghany, Marc

AU - Rehermann, Barbara

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background & Aims Chronic hepatitis C virus infection activates an intrahepatic immune response, leading to increased expression of interferon (IFN)-stimulated genes and activation of natural killer (NK) cells - the most prevalent innate immune cell in the liver. We investigated whether the elimination of hepatitis C virus with direct-acting antiviral normalizes expression of IFN-stimulated genes and NK cell function. Methods We used multicolor flow cytometry to analyze NK cells from the liver and blood of 13 HCV-infected patients who did not respond to treatment with pegylated interferon and ribavirin. Samples were collected before and during IFN-free treatment with daclatasvir and asunaprevir and compared with samples from the blood of 13 healthy individuals (controls). Serum levels of chemokine C-X-C motif ligand (CXCL) 10 or CXCL11 were measured by enzyme-linked immunosorbent assay. Results Before treatment, all patients had increased levels of CXCL10 or CXCL11 and a different NK cell phenotype from controls, characterized by increased expression of HLA-DR, NKp46, NKG2A, CD85j, signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). NK cells from patients also had increased degranulation and decreased production of IFNγ and tumor necrosis factor α compared with NK cells from controls. Nine patients had an end-of-treatment response (undetectable virus) and 4 had virologic breakthrough between weeks 4 and 12 of therapy. A rapid decrease in viremia and level of inflammatory cytokines in all patients was associated with decreased activation of intrahepatic and blood NK cells; it was followed by restoration of a normal NK cell phenotype and function by week 8 in patients with undetectable viremia. This normalized NK cell phenotype was maintained until week 24 (end of treatment). Conclusions Direct-acting antiviral-mediated clearance of HCV is associated with loss of intrahepatic immune activation by IFNα, which is indicated by decreased levels of CXCL10 and CXCL11 and normalization of NK cell phenotype and function.

AB - Background & Aims Chronic hepatitis C virus infection activates an intrahepatic immune response, leading to increased expression of interferon (IFN)-stimulated genes and activation of natural killer (NK) cells - the most prevalent innate immune cell in the liver. We investigated whether the elimination of hepatitis C virus with direct-acting antiviral normalizes expression of IFN-stimulated genes and NK cell function. Methods We used multicolor flow cytometry to analyze NK cells from the liver and blood of 13 HCV-infected patients who did not respond to treatment with pegylated interferon and ribavirin. Samples were collected before and during IFN-free treatment with daclatasvir and asunaprevir and compared with samples from the blood of 13 healthy individuals (controls). Serum levels of chemokine C-X-C motif ligand (CXCL) 10 or CXCL11 were measured by enzyme-linked immunosorbent assay. Results Before treatment, all patients had increased levels of CXCL10 or CXCL11 and a different NK cell phenotype from controls, characterized by increased expression of HLA-DR, NKp46, NKG2A, CD85j, signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). NK cells from patients also had increased degranulation and decreased production of IFNγ and tumor necrosis factor α compared with NK cells from controls. Nine patients had an end-of-treatment response (undetectable virus) and 4 had virologic breakthrough between weeks 4 and 12 of therapy. A rapid decrease in viremia and level of inflammatory cytokines in all patients was associated with decreased activation of intrahepatic and blood NK cells; it was followed by restoration of a normal NK cell phenotype and function by week 8 in patients with undetectable viremia. This normalized NK cell phenotype was maintained until week 24 (end of treatment). Conclusions Direct-acting antiviral-mediated clearance of HCV is associated with loss of intrahepatic immune activation by IFNα, which is indicated by decreased levels of CXCL10 and CXCL11 and normalization of NK cell phenotype and function.

KW - Immune Regulation

KW - ISG

KW - NS3 Inhibitor

KW - NS5A Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84931378182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931378182&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2015.03.004

DO - 10.1053/j.gastro.2015.03.004

M3 - Article

C2 - 25754160

AN - SCOPUS:84931378182

VL - 149

SP - 190

EP - 200

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

M1 - 59663

ER -